Moreover, inhibiting MMP-9 during the acute stages of cardiovascular disease may provide favorable outcomes, but limiting MMP-9 as the disease progresses may curtail compensatory remodeling and contribute to a progression into HF [30,36]. Here, MMP9 is linked to cardiovascular disorder.